Your session is about to expire
← Back to Search
Arm C: RPTR-147:2 for Lymphoma
Study Summary
This trial is testing a new drug, RPTR-147, to see if it is safe and works well against cancer.
- Lymphoma
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have there been prior studies conducted involving the RPTR-147:2 formulation?
"Arm C: RPTR-147:2 was first tested at City of Hope in 2010 and since then, 249 studies have been concluded. Over 900 trials are presently recruiting participants with a majority hosted in New york's metropolitan area."
Has the FDA sanctioned RPTR-147:2 in Arm C?
"The risk-benefit analysis conducted by our team at Power awarded Arm C: RPTR-147:2 a score of 1 due to the limited clinical evidence supporting its safety and efficacy."
How many participants are engaging in this experiment?
"This medical trial has wrapped up its recruitment process, last revised on August 30th 2022. If you are in search of alternative studies, there is an abundance with 2136 clinical trials for those diagnosed with lymphoma and 961 concerning RPTR-147:2 that still accept participants."
Is the application process for this trial currently accessible?
"The information found on clinicaltrials.gov reveals that this particular investigation is not currently recruiting any participants; the initial post was made in October 2018 and last edited in August 2022. Nonetheless, there are over three thousand other studies actively seeking volunteers right now."
What aims is this research seeking to achieve?
"At the conclusion of cycle 1, this trial will measure its primary outcome—the number of patients with dose-limiting toxicities. The secondary objectives include best overall response per modified RECIST v1.1 (for solid tumors) or Lugano classification (for lymphoma), immunogenicity of RPTR-147 as monotherapy and in combination with pembrolizumab measured by counting anti-RPTR/Pembro antibodies, and progression free survival evaluated using modified RECIST v1.1 for solid tumor detection or Lugano Classification for detecting lymphomas."
How many locations are participating in this investigation?
"This trial is being conducted across 11 different medical sites, including NYU Langone Health in New york City, Sarah Cannon Research Institute in Nashville, and Carolina BioOncology Institute located near Huntersville."
What therapeutic purpose is Arm C: RPTR-147:2 typically employed for?
"Arm C: RPTR-147:2 is a common course of treatment for malignant neoplasms and has also been used to treat unresectable melanoma, microsatellite instability high cancers, and progression after chemotherapy."
Share this study with friends
Copy Link
Messenger